PBAC's latest decision on Rsv pre-fusion f protein vaccine (rsvpref): Recommended with restriction (2024). Considered for Prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV) in adults aged 75 years and older, Aboriginal and Torres Strait Islander peoples aged 60 to 74 years, and adults aged 60 to 74 years with at least one risk factor for severe RSV disease.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adults aged 75 years and above; Aboriginal and Torres Strait Islander peoples aged 60 to 74 years; adults aged 60 to 74 years with at least one risk condition for severe RSV disease (cardiac disease, chronic respiratory condition, immunocompromising condition, chronic metabolic disorder, chronic kidney disease stage 4 or 5, or chronic neurological condition).
Therapy area
Vaccines
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
RSV-LRTI
Key trials
RENOIR
Comparator
no vaccine (standard of care)
Economic model
CUA
ICER note
ICER values not stated in the public document; commercial-in-confidence or not presented in detail in the sections provided.